It is well-known that the human thyroid concentrates iodine more than 100 times the concentration in plasma. Also well-known is the fact that large amounts of stable iodine in the diet can limit thyroid uptake of total iodine; this is the basis for administering potassium iodide following a release of radioiodine from a nuclear reactor accident or nuclear weapon detonation. Many researchers have shown enhanced concentrations of both organic and inorganic iodine in saliva and breast milk.
127
I) in the diet limit uptake of iodine by the thyroid leads one to generalize that stable iodine in the diet may also limit thyroid uptake of pertechnetate. While there is at least one report that iodine in the diet blocks uptake of 99m TcO 4 − by the thyroid and salivary glands (which have the same Na/I symporter, the biochemical concentration mechanism), the level of protective effect seen for blocking radioactive iodine is not expected for 99 TcO 4 − because pertechnetate does not become organically bound in the thyroid and thus is not retained for months the way iodide is.
While it does account for Tc concentration in the thyroid, the existing ICRP biokinetic model for technetium does not take enhanced concentrations in salivary gland and breast tissue into account. From the survey of the nuclear medicine literature, it is not possible to compute the effect of stable iodine in the diet on the dose per unit intake factors for 99 Tc without developing an improved biokinetic model for technetium. Specific experiments should be designed to quantitatively evaluate 99 TcO 4 − metabolism, excretion, and secretion, as well as to evaluate its chemical toxicity
It is recommended that the ICRP reexamine its biokinetics models for Tc based on nuclear medicine data that have accumulated over the years. In particular, the ICRP ignores the lactation pathway, the enhanced concentration of Tc in breast and breast milk, and enhanced concentration of Tc (and I) in the salivary glands as well as in the thyroid. The ICRP should also explicitly incorporate the effect of stable iodine in the diet into both its models for iodine and technetium. The effect of concentration of Tc in breast milk needs further study for dosimetric implications to nursing infants whose mothers may ingest 99 TcO 4 − from groundwater sources. The ICRP should also investigate the possibility of enhanced concentration of both I and Tc in the nonlactating female breast.
To do these re-evaluations of biokinetic models, new experiments designed specifically to evaluate these questions concerning the biokinetics of Tc and I are needed. 
Introduction
The effective dose or effective dose equivalent due to intakes of radioactive 129 I depends on what fraction of iodine in the bloodstream is taken up by the thyroid, the retention half-time for the iodine that is taken up by the thyroid, and the thyroid mass. The fraction of iodine taken up by the thyroid varies inversely with the dietary intake of stable, nonradioactive iodine ( 127 I). If there is significant stable iodine in drinking water or another dietary source, uptake fractions will be lower, and dose per unit intake (i.e., rems/nCi or Sv/Bq) will be correspondingly lower. TcO 4 − has shown that, like iodine, it is concentrated by the thyroid gland and salivary glands, and preferentially secreted in breast milk and saliva. It follows that the dose per unit intake of 99 Tc will also be lowered by intake of large amounts of stable iodine in the diet. In a study that examined how thyroid pertechnetate uptake with and without thyroid-stimulating hormone (TSH) suppression changes as a function of increasing iodine supply, Reinhardt et al. conclude that "the influence of TSH on the thyroid pertechnetate uptake seems to be secondary compared with the influence of the iodine supply" (Reinhardt et al. 1998 ). With lowered uptake comes lower dose. This paper is a literature review of the dosimetry of intakes of technetium, with the goal of examining the significance of stable iodine in the diet on technetium dosimetry, and suggesting research needs to fill the gaps. It examines similarities and differences of technetium and iodine in the context of dosimetry.
Iodine

Uptake of Iodine by the Thyroid
A literature search was undertaken to find the correlation of thyroid uptake fraction and thyroid retention time for iodine as a function of stable iodine intake. It is reasonable to hypothesize that there is non-zero covariance (or contravariance) of thyroid uptake fraction, thyroid mass, and iodine retention time in the thyroid with dietary intake of stable iodine. The first formal study of the effects of these three variables (Dunning, Jr. and Schwarz 1981) assumed that each was independent of the other two, an assumption that is questionable, and did not examine the dependence of these variables on stable iodine intake from drinking water and diet. The most comprehensive review of iodine metabolism published to date is available on the internet (National Cancer Institute 1997). Recently, other researchers have assumed that thyroid mass and iodine uptake fraction are "highly correlated" (they use a correlation coefficient of 0.9) to develop age-specific uncertainty of the Figure 1 shows the equivalent dose per unit intake via ingestion for various adult organs and tissues using the newest International Commission on Radiological Protection (ICRP) biokinetic models, as computed by IMBA-Expert (James 2003) . With the ICRP's default tissue weighting factor w T = 0.05, the default fractional absorption of I from the gut, f 1 , of 1.0, the default thyroid uptake of 30%, and the default half-time in the thyroid of 80 days, the equivalent dose to the thyroid is 4,900 times greater than the next most highly exposed tissue. Note that the breast receives less dose than almost any other tissue, and that the salivary glands are not listed. These two tissues probably receive much larger doses than indicated in the ICRP model, as shown below for Tc. 
Thyroid Blocking by Intake of Stable Iodine
A simple mathematical description of iodine uptake is given by This equation is plotted in Figure 2 assuming a daily thyroid mass uptake of 70 µg and a recycling fraction of 0.85. At the level of potassium iodide (KI) currently recommended in the USA for thyroid blocking in case of an emergency, 130 mg KI (i.e., 100 mg of I) per day (U.S. Food and Drug Administration (FDA) 2001), the fractional uptake is 0.07%. It must be noted, however, that simply assuming uniform dilution of any intake of iodine in a 70 kg person with a 20 g thyroid would result in a fractional uptake of 20/70,000 = 0.029%, probably a limiting value. Furthermore, blocking the thyroid results in no reduction of dose to other tissues, so there is a limiting value of thyroid blocking that results in any meaningful dose reduction. Figure 2 it can be seen that such an intake doesn't suppress the fractional uptake by the thyroid. However, as shown by Moeller (2003) , the simple dilution of groundwater iodine by stable 127 I from other dietary sources places an upper bound on doses due to intake of 129 I. The presumption here is that large intakes of stable 127 I will reduce uptake of not only the thyroid, but also the salivary glands and the breast.
Retention Half-time of Iodine in the Thyroid
The retention half-time for iodine in the thyroid increases with age, from 15 to 25 days for newborns, up to average values of about 80 days in adults, with wide variability (National Cancer Institute 1997). The two-step process of 1) vigorous concentration of iodine in the thyroid by the Na/I symporter transport system (Van Sande et al. 2003) and the "organification" (covalent binding of iodine to thyroglobulin, resulting in an iodinated thyroglobulin) of the iodine once in the thyroid lead to the high concentration and long retention, respectively (Meller and Becker 1998).
Technetium
A review and analysis of the literature on 99 TcO 4 − intake and uptake follows. The magnitude of reduction of effective dose and effective dose equivalent as a function of stable iodine intake in the diet is evaluated based on this information.
Chemical Speciation of Technetium in the Environment
"Some radionuclides, such as technetium, uranium, and plutonium, may be present in more than one oxidation state in the environment. (Langmuir 1997 ).
For purposes of this report, then, any technetium taken in from groundwater is assumed to be in the chemical form of pertechnetate.
In a report on research needs for radiation protection, the National Council on Radiation Protection and Measurements (NCRP) stated that technetium "has an extremely low affinity for soil and sediment particles, and an extremely high degree of bioavailability. Making this radionuclide even more challenging is that is has been identified as presenting a higher risk as a chemical toxicant than as a radioactive material" (National Council on Radiation Protection and Measurements (NCRP) 1993). "In terms of specifics, it interacts as a sulfur analog in metabolic and chemical processes. This can lead to the metabolic dysfunction and death of the exposed organism. Evidence indicates that this interaction is most pronounced with the complex proteins used in electron transport; thus in the case of plants, photosynthesis and protein metabolism are affected. While there is a wealth of information for the soil-plant system, its implications for the subsequent food pathways have been neglected and require attention" (NCRP 1993).
The ICRP Biokinetic Models for Technetium
The early ICRP work quotes the fractional absorption of Tc from the gut, f 1 , as 0.5 for persons over age 1, and 1.0 for persons under age 1 (International Commission on Radiological Protection (ICRP) 1993). More recently, the values of f 1 are given as 1 for age 3 months and 0.8 for age above 3 months (International Commission on Radiological Protection (ICRP) 1995).
The ICRP recognizes that "technetium administered intravenously as pertechnetate is concentrated in the thyroid, gastrointestinal tract and liver" (International Commission on Radiological Protection (ICRP) 1993). In 1980, the ICRP "adopted a simplified model to describe the retention of technetium after entry into body fluids. Of technetium leaving the transfer compartment 0.04 is assumed to be translocated to the thyroid and retained with a half-time of 0.5 days. Further fractions, 0.1 and 0.03, are assumed to be translocated to the stomach wall and liver, respectively. The remaining fraction is assumed to be uniformly distributed throughout all organs and tissues of the body other than they thyroid, 0.75, 0.20, and 0.05 are assumed to be retained with biological half-times of 1.6, 3.7, and 22 days, respectively. For technetium the biological half-time in the transfer compartment is taken to be 0.02 days. No further data appear to have been published which suggest these biokinetics parameters need to be modified and they are therefore adopted here… A urinary to fecal excretion ratio of 1:1 is assumed for technetium that has entered the transfer compartment" (International Commission on Radiological Protection (ICRP) 1993).
The biokinetics data for the adult are adopted for infants and children. A plot of the results of the ICRP models described above is shown in Figure 3 . There is no calculation for the salivary glands, and the breast receives no enhanced dose when compared to all other tissues not specifically listed in Figure 3 .
Technetium Concentrates in the Salivary Glands
Technetium as pertechnetate concentrates in the salivary glands and thyroid, and is routinely used for imaging of these tissues because Tc-pertechnetate was 0.46%+/-0.16% and 0.43%+/-0.17% in parotid and submandibular glands, respectively" (Bohuslavizki et al. 1998 ). In another study, these authors also showed that amifostine protected the salivary glands when administered before and during high dose radioiodine therapy.
The mass of pairs of major salivary glands in adult males and adult females is given in Table 1 , along with the uptake fractions. The concentration factors are % uptake divided by % body mass, and the salivary glands average an 8.9-fold concentration factor. 
Technetium Concentrates in the Thyroid
There is considerable use of TcO 4 − is rapidly eliminated from the body, the pool available for recycling back into the thyroid dwindles rapidly.
Nonetheless, as shown in Table 1 , accumulation of 3% of an administered dose of 99m TcO 4 − in the thyroid amounts to a more than 100-fold concentration enhancement over other tissues. In terms of effective dose or effective dose equivalent, using a tissue weighting factor of w thyroid = 0.05, the relative contributions of the thyroid dose to the effective dose for an administration of 1 Bq/kg is roughly (0.05)(100 Bq/kg). The contribution of all other tissues is roughly (0.95)(0.97 Bq/kg). The ratio of thyroid contribution to the contribution from all other tissues is about 5:1.
Technetium Concentrates in the Breast and Breast Milk
One study of a nursing mother measured 10.8% of total injected For a pure beta emitter like 99 Tc, a reasonable approximation is to assume that the energy emitted in a tissue is absorbed in a tissue. The rate at which energy is emitted in a tissue is directly proportional to the concentration of a radionuclide in the tissue.
The average concentration in the breast , C is the mass-weighted average of concentration in breast parenchymal tissue (C breast ) and concentration in breast milk (C milk ) produced and stored in that tissue. This average for dosimetric purposes would be 
where C denotes concentration (Bq/kg) and m denotes mass (kg). It is difficult to infer the dose enhancement to the breast of the lactating woman without simultaneous measurements of concentration in both the body and the milk.
One indirect approach is to estimate the parameters needed for solving Equation (2) from reference values. The mass of milk in the breast is assumed to be time-varying, increasing from zero to a maximum between feedings, and then decreasing to zero again, with an average of 0. In the former case, concentration drops rapidly with a half-time of 4-5 hours. In the latter case, which is of interest here, the concentration will reach an equilibrium value of 10% of the daily 99 Tc intake diluted in 850 mL of milk. 
Using Equation (2) with a 7.73-fold bioconcentration of 99 TcO 4 − in milk (C milk = 7.73C breast ),
, significantly larger than C breast , the concentration in the parenchymal tissue of the breast of the nursing mother. For a pure beta-emitter like 99 Tc, this increased concentration increases the dose to breast by the same factor when compared to other soft tissues.
The value of 1.65 is a lower bound, because is assumes no enhanced concentration in the soft tissues of the breast, only enhanced concentration in the milk, a simplifying assumption since at least a portion of the mammary parenchymal tissue must also have enhanced concentrations in order to produce milk with enhanced concentrations. On the other hand, the mass of the nonlactating breast may be significantly lower than the mass of the lactating breast just after nursing, reducing the value. This research was not able to establish which of the two effects predominates.
It is unknown what concentration enhancement occurs, if any, in non-lactating breast tissue. 11 Assuming no change in the daily intake of water by nursing mothers when compared to nonnursing women, the daily intake by the nursing mother of
The dose to the nursing newborn from enhanced concentrations of 99 Tc in breast milk would be increased. The daily intake by the nursing infant is 10% of the mother's intake, or perhaps 10% of the mother's intake multiplied by the mother's uptake from the gut (= 0.1f 1 ) , that is, 8% if f 1 is 0.8. If the infant's mass is less than 10% or 8% of the mother's mass, i.e., less than 6 kg (13.2 pounds) or 4.8 kg (8.8 lb), respectively, in this calculation, then the activity taken in per unit body mass is higher for the infant than for the mother. If higher values of 99 TcO 4 − concentration in breast milk are used, then infant intakes will be proportionately higher. 
Conclusions
It is well-known that the human thyroid concentrates iodine over 100-fold what is in plasma. Also well-known is the fact that large amounts of stable iodine in the diet can limit thyroid uptake of total iodine. There are also a host of papers showing enhanced concentrations of both organic and inorganic iodine in saliva and breast milk, although those data are not reviewed here.
Technetium-99 in groundwater will be found in the form of pertechnetate 99 TcO 4 − . The nuclear medicine literature shows that pertechnetate concentrates in the thyroid, salivary glands, and lactating breast in addition to the stomach, liver, and alimentary tract as currently recognized by the ICRP. The fact that large intakes of stable iodine ( 127 I) in the diet limit uptake of iodine by the thyroid leads one to generalize that stable iodine in the diet may also limit thyroid uptake of pertechnetate. While there is at least one report that iodine in the diet blocks uptake of iodine would block some of the uptake of Tc, the dose reducing effect of this blocking would not be as large as that for radioiodine because pertechnetate does not become organically bound in the thyroid and thus is not retained for months the way iodide is.
From the survey of the nuclear medicine literature, it is not possible to compute the effect of stable iodine in the diet on the dose per unit intake factors for 99 Tc without developing an improved biokinetic model for technetium. Specific experiments should be designed to quantitatively evaluate 99 TcO 4 − metabolism, excretion, and secretion, as well as to evaluate its chemical toxicity 13 
Recommendations
To do these re-evaluations, new experiments designed specifically to evaluate these questions concerning the biokinetics of Tc and I are needed.
